Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E10.18 EPS (ttm)10.61 Insider Own0.30% Shs Outstand221.60M Perf Week-3.78%
Market Cap23.87B Forward P/E9.24 EPS next Y11.69 Insider Trans290.34% Shs Float218.87M Perf Month-9.80%
Income2.37B PEG0.81 EPS next Q2.58 Inst Own93.30% Short Float2.00% Perf Quarter14.02%
Sales5.30B P/S4.51 EPS this Y3.60% Inst Trans-1.33% Short Ratio1.97 Perf Half Y1.08%
Book/sh53.01 P/B2.04 EPS next Y7.20% ROA14.60% Target Price137.85 Perf Year-14.09%
Cash/sh10.69 P/C10.10 EPS next 5Y12.60% ROE21.80% 52W Range72.67 - 127.74 Perf YTD-0.14%
Dividend- P/FCF11.51 EPS past 5Y26.80% ROI16.90% 52W High-15.68% Beta1.46
Dividend %- Quick Ratio3.80 Sales past 5Y17.40% Gross Margin92.10% 52W Low48.22% ATR3.46
Employees3082 Current Ratio4.30 Sales Q/Q26.70% Oper. Margin43.40% RSI (14)42.20 Volatility2.30% 3.03%
OptionableYes Debt/Eq0.21 EPS Q/Q-3.90% Profit Margin44.80% Rel Volume0.98 Prev Close108.00
ShortableYes LT Debt/Eq0.20 EarningsMay 06 BMO Payout0.00% Avg Volume2.23M Price107.71
Recom2.10 SMA20-4.85% SMA50-1.36% SMA2003.68% Volume381,625 Change-0.27%
Apr-28-20Initiated Cantor Fitzgerald Neutral $121
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Jul-08-20 01:21PM  
Jul-07-20 06:48PM  
10:00AM  
Jul-06-20 09:06AM  
Jul-02-20 12:10PM  
09:12AM  
08:48AM  
08:45AM  
Jul-01-20 09:43AM  
Jun-30-20 02:34PM  
Jun-29-20 02:00AM  
Jun-26-20 10:37AM  
Jun-25-20 01:44PM  
12:18PM  
10:50AM  
Jun-24-20 09:12AM  
Jun-23-20 10:24AM  
Jun-17-20 08:30AM  
06:30AM  
05:51AM  
Jun-13-20 04:22PM  
Jun-12-20 10:09AM  
08:45AM  
08:20AM  
Jun-11-20 10:36PM  
11:10AM  
Jun-10-20 05:51AM  
Jun-09-20 01:51PM  
Jun-08-20 02:48PM  
12:29PM  
Jun-05-20 11:32AM  
Jun-04-20 06:30AM  
Jun-02-20 10:53AM  
Jun-01-20 05:50PM  
May-29-20 07:38PM  
04:32PM  
09:38AM  
May-28-20 03:36PM  
02:16PM  
09:49AM  
09:27AM  
06:03AM  
May-27-20 01:05PM  
May-15-20 04:48PM  
May-14-20 01:47PM  
09:31AM  
May-12-20 05:07PM  
12:34PM  
08:55AM  
May-08-20 06:35PM  
04:24PM  
May-07-20 01:24PM  
11:50AM  
May-06-20 04:22PM  
01:31PM  
12:25PM  
11:26AM  
11:19AM  
08:48AM  
08:05AM  
06:30AM  
May-05-20 04:58PM  
04:30PM  
04:02PM  
03:10PM  
12:42PM  
11:13AM  
10:42AM  
09:36AM  
08:40AM  
08:13AM  
07:49AM  
07:14AM  
07:00AM  
May-04-20 12:10PM  
11:07AM  
09:15AM  
May-02-20 07:31AM  
May-01-20 08:30AM  
Apr-30-20 05:50PM  
Apr-29-20 12:34PM  
Apr-28-20 06:27AM  
Apr-24-20 10:35AM  
Apr-22-20 03:36PM  
10:30AM  
Apr-21-20 04:37PM  
12:29PM  
Apr-20-20 02:56PM  
02:35PM  
11:17AM  
10:00AM  
08:46AM  
08:30AM  
Apr-16-20 06:50PM  
Apr-12-20 06:34PM  
Apr-10-20 11:40AM  
Apr-09-20 05:25PM  
Apr-06-20 06:26PM  
Apr-02-20 01:04PM  
10:19AM  
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale114.696,853785,98128,218Jun 09 05:05 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy82.0181,3796,673,9357,841,556Mar 18 06:46 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy79.7650,9024,059,7927,766,918Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy76.51102,4217,836,5857,720,234Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy78.76265,29820,894,7537,626,298Mar 18 06:45 PM